Olivier Ameisen

Olivier Ameisen (June 25, 1953 – July 18, 2013) was a French-American cardiologist[1] who wrote a best-selling book about curing alcoholism using the drug baclofen.

Olivier Ameisen
Born(1953-06-25)25 June 1953
Died18 July 2013(2013-07-18) (aged 60)
Paris, France
NationalityFrench
EducationParis Descartes University
OccupationCardiologist
FamilyJean-Claude Ameisen (brother)

Education and career

Ameisen graduated in 1969 from Université René Descartes (Paris V) Faculté de Médecine Cochin Port-Royal.[2]

He had been professor of medicine at the Weill Medical College of Cornell University and an attending physician at New York Presbyterian Hospital for fifteen years, when he opened a cardiology practice in Manhattan in 1994.[3] He was appointed visiting professor of medicine at the State University of New York Downstate Medical Center in 2008 based on his work on the mechanisms and treatment of addiction.

Baclofen

After hearing anecdotal reports that the muscle relaxant baclofen was, like naltrexone, acamprosate and topiramate, modestly effective at reducing the cravings of addictions, he experimented on himself, and proposed a new treatment model for addiction that is evidence-based. He first postulated that unlike other diseases for which suppression of symptoms is not associated with improvement of prognosis (such as: bacterial pneumonia, relief of unstable angina with medical means without surgery etc...), in addiction, suppression of symptoms (craving, preoccupation, thoughts etc...) should suppress the disease altogether since addiction is, as he observed, a "symptom-driven disease". Of all "anticraving" medications used in animals, only one - baclofen - has the unique property of suppressing the motivation to consume cocaine, heroin, alcohol, nicotine and d-amphetamine. The effect is dose-dependent.[4]

Since complete suppression of dependence using a medication had never been described in the medical literature, Ameisen wrote up his own case report. The peer reviewed journal, Alcohol and Alcoholism, published it on December 13, 2004, after praising the paper. In his paper, as in those that followed in JAMA, Lancet, CNS Drugs etc., Ameisen urged for randomized trials to test suppression of alcohol dependence using high-dose baclofen.[5]

In 2008, Ameisen wrote a best-selling book, The End Of My Addiction, published in France as Le Dernier Verre (The Last Glass), describing his experience of curing his alcoholism with baclofen.[6]

In 2007, an Italian team also showed the effectiveness and the safety of baclofen as a treatment for alcohol addiction.[7]

Death

Ameisen died of a myocardial infarction on July 18, 2013.[1]

gollark: Well, yours is old, although I think it has good custom ROM availability.
gollark: It's required for Android 8.1 and up with Google services.
gollark: Any new one?
gollark: It's a standard for basically everything.
gollark: Project Treble.

References

  1. "Olivier Ameisen, l'apôtre du Baclofène, est mort". Le Monde.fr. Lemonde.fr. 2013-07-19. Retrieved 2013-07-20.
  2. "Baclofène - Olivier Ameisen - traitement alcoolisme - BACLOFENE - Olivier Ameisen". olivierameisen.fr. Retrieved 8 January 2016.
  3. Russell Goldman (14 January 2009), Doctor Claims Cure for Alcoholism in a Pill, ABC News
  4. Ameisen O (August 2005). "Naltrexone treatment for alcohol dependency". JAMA. 294 (8): 899–900. doi:10.1001/jama.294.8.899-b. PMID 16118379.
  5. Ameisen O (2005). "Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician" (PDF). Alcohol and Alcoholism. 40 (2): 147–50. doi:10.1093/alcalc/agh130. PMID 15596425.
  6. Hugh Schofield (6 Dec 2008), "France abuzz over alcoholic 'cure'", BBC News
  7. Addolorato G, Leggio L, Ferrulli A, et al. (December 2007). "Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study". Lancet. 370 (9603): 1915–22. doi:10.1016/S0140-6736(07)61814-5. PMID 18068515.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.